Leerink Partnrs Decreases Earnings Estimates for Bruker

Bruker Co. (NASDAQ:BRKR) – Leerink Partnrs decreased their FY2024 earnings per share estimates for Bruker in a report released on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $2.38 for the year, down from their prior estimate of $2.61. The consensus estimate for Bruker’s current full-year earnings is $2.61 per share. Leerink Partnrs also issued estimates for Bruker’s Q3 2025 earnings at $0.70 EPS.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The company had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.74 EPS.

BRKR has been the topic of a number of other reports. Citigroup cut their price objective on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday. Wells Fargo & Company cut their price objective on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday. TD Cowen decreased their target price on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday. Wolfe Research downgraded shares of Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Finally, Barclays cut their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research note on Wednesday. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.36.

Bruker Price Performance

Shares of BRKR opened at $58.98 on Thursday. The stock has a fifty day moving average price of $63.97 and a 200 day moving average price of $66.51. The company has a market cap of $8.93 billion, a P/E ratio of 24.47, a PEG ratio of 2.32 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75. Bruker has a 12 month low of $54.55 and a 12 month high of $94.86.

Hedge Funds Weigh In On Bruker

A number of large investors have recently bought and sold shares of BRKR. First Horizon Advisors Inc. boosted its stake in shares of Bruker by 120.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after acquiring an additional 218 shares during the period. Covestor Ltd boosted its holdings in shares of Bruker by 139.1% during the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 210 shares in the last quarter. UMB Bank n.a. grew its holdings in Bruker by 115.3% during the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after acquiring an additional 354 shares during the last quarter. Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Bruker in the second quarter valued at about $52,000. Finally, GAMMA Investing LLC increased its position in shares of Bruker by 81.0% during the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after buying an additional 388 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.